Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsPsychopharmacology — fitness to drive

Psych MEQs / SAQs · Psychopharmacology — fitness to drive

Psychotropics, sedation and driving (MEQ)

FRANZCP-style MEQ on BZD/zopiclone residual impairment, older-driver polypharmacy crash risk, counselling and documentation.

20 marks20 min2 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 68-year-old man with generalised anxiety and chronic insomnia drives a private car to work at 06:30. He has taken diazepam 5 mg three times daily for 4 years and zopiclone 7.5 mg most nights. His GP recently added sertraline 50 mg daily. He reports two near-misses in the past month and occasional wine with dinner. He asks if he is 'fine to drive because the sleeping tablet is not a benzodiazepine.' (i) Interpret his crash-risk profile using epidemiological evidence. (ii) Explain residual hypnotic impairment and the role of SDLP science. (iii) Outline immediate driving advice and medication review priorities. (iv) State how concurrent BZD + antidepressant risk applies in older drivers. (v) Document the key elements of a fitness-to-drive counselling note including licence-class caveats. (20 marks)

Model answer

Reveal model answerShowHide

(i) Crash-risk profile. Age 68 with chronic long-half-life BZD (diazepam), regular zopiclone, new SSRI, near-misses and alcohol use is a high-risk stack. Thomas: BZD use roughly doubles MVC risk in case-control synthesis; older drivers are vulnerable.[2] Hemmelgarn: long-half-life BZDs elevate elderly crash risk.[3] Barbone and broader medicinal-drug reviews support population-level BZD–accident association; Gustavsen links zopiclone (and other hypnotics) prescriptions to traffic accident risk — zopiclone is not “safe because not a BZD.”[5][8][10] Dassanayake meta-analysis consolidates BZD (and related) impairment evidence.[7]

(ii) Residual impairment and SDLP. Verster: benzodiazepine hypnotics and zopiclone impair on-road driving the morning after bedtime dosing; magnitude depends on dose, half-life and hours since dose. SDLP (standard deviation of lateral position) is the experimental gold-standard weaving metric used to quantify residual impairment relative to alcohol-calibrated effects.[1][4] Early commute at 06:30 after night zopiclone is precisely the residual window.

(iii) Immediate advice and medication review. Explicit temporary no-drive (or tightly restricted driving) until sedative load reduced and near-misses cease; no alcohol with sedatives; arrange safe transport for work; start planned BZD taper (not abrupt stop without plan); stop or minimise zopiclone with non-drug insomnia care; continue sertraline with monitoring but do not blame the SSRI alone for the entire risk stack; early review for sedation, anxiety rebound and sleep.[1][4][7][9]

(iv) Concurrent BZD + antidepressant. Fournier: concurrent benzodiazepines and antidepressants increase MVA risk in older drivers, particularly with long-acting BZDs — his new sertraline on a diazepam background is exactly this phenotype for shared decision and deprescribing urgency.[6]

(v) Documentation. Record: licence class (private light vehicle vs any commercial duties), current mental state and near-miss history, full sedative/alcohol reconciliation, specific advice given (temporary restriction, no alcohol, residual zopiclone warning), patient understanding, medication change plan, review date, and reference to local fitness-to-drive standards (e.g. Austroads principles) without inventing statute numbers; note higher bar if occupational driving emerges.[1][9]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References10ShowHide
  1. [1]Verster JC, Mets MA. Psychoactive medication and traffic safety Int J Environ Res Public Health, 2009.PMID 19440432
  2. [2]Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association Can Fam Physician, 1998.PMID 9585853
  3. [3]Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly JAMA, 1997.PMID 9207334
  4. [4]Verster JC, Veldhuijzen DS, Volkerts ER. Residual effects of sleep medication on driving ability Sleep Med Rev, 2004.PMID 15233958
  5. [5]Gustavsen I, Bramness JG, Skurtveit S, et al. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam Sleep Med, 2008.PMID 18226959
  6. [6]Fournier JP, Wilchesky M, Patenaude V, et al. Concurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case-Control Study CNS Drugs, 2015.PMID 26847674
  7. [7]Dassanayake T, Michie P, Carter G, et al. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence Drug Saf, 2011.PMID 21247221
  8. [8]Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use Lancet, 1998.PMID 9802269
  9. [9]Brunnauer A, Herpich F, Zwanzger P, et al. Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies Int J Neuropsychopharmacol, 2021.PMID 34038545
  10. [10]Orriols L, Salmi LR, Philip P, et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies Pharmacoepidemiol Drug Saf, 2009.PMID 19418468
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousPsychotropics in CKD and cirrhosis (MEQ)Psychopharmacology — renal and hepatic diseaseNextQuality improvement and patient safety in psychiatry (MEQ)Public-community — quality improvement and patient safety